For the quarter ended June 2023, PRA Group (PRAA) reported revenue of $209.24 million, down 19% over the same period last year. EPS came in at -$0.10, compared to $0.91 in the year-ago quarter.
The reported revenue represents a surprise of +2.46% over the Zacks Consensus Estimate of $204.21 million. With the consensus EPS estimate being -$0.16, the EPS surprise was +37.50%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PRA Group performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Cash Collections by Geography- Total Cash Collections: $419.32 million versus $393.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -5.6% change.
- Revenues- Other revenue: $3.81 million compared to the $5.15 million average estimate based on four analysts. The reported number represents a change of +212.6% year over year.
- Revenues- Portfolio income: $184.29 million versus $185.94 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5% change.
- Revenues- Changes in expected recoveries: $21.14 million versus $24.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -62.6% change.
Shares of PRA Group have returned -4.6% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpPRA Group, Inc. (PRAA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
